X-Linked Adrenoleukodystrophy (ABCD1) Gene Mutation Analysis, Blood
X-linked adrenoleukodystrophy (X-ALD) is X-linked recessive peroxisomal disorder caused by a deficiency of adrenoleukodystrophy protein (ALDP) and resultant accumulation of very long-chain fatty acids (VLCFAs) in plasma and tissues. It occurs primarily in males and affects the nervous system white matter and the adrenal cortex. There are three distinct types of X-linked adrenoleukodystrophy: (1) childhood cerebral form, (2) an adrenomyeloneuropathy type, and (3) a form called Addison disease only. The childhood cerebral form manifests most commonly between ages of 4 and 10 years. It initially resembles attention-deficit disorder or hyperactivity; progressive impairment of cognition, behavior, vision, hearing, and difficulty swallowing, poor coordination, and impaired adrenal gland function. The adrenomyeloneuropathy type appears between early adulthood and middle age. Affected individuals develop progressive stiffness and weakness in their legs (paraparesis), sphincter disturbances, sexual dysfunction, urinary and genital tract disorders, and often show changes in behavior and thinking ability. In Addison disease, primary adrenocortical insufficiency can begin anytime between childhood and adulthood and most commonly by age 7.5 years, without evidence of neurologic abnormality; however, some degree of neurologic disability usually develops by middle age. This disease is the mildest of the three types. The prevalence of X-linked adrenoleukodystrophy is 1 in 20,000 to 50,000 individuals worldwide.
X-ALD is caused by mutations in the ABCD1 gene on chromosome X at position q28. Mutations in X-ALD result in a deficiency of adrenoleukodystrophy protein (ALDP). This deficiency disrupts the transportation and subsequent breakdown of very long-chain fatty acids (VLCFAs) causing abnormally high levels of these fats in the body. The accumulation of VLCFAs may be toxic to both the cells of adrenal cortex and myelin. The diagnosis of X-ALD is based on clinical features, brain MRI findings, and elevated level of very long chain fatty acids (VLCFA) in serum or plasma. The diagnosis is confirmed in males by measuring enzyme levels and/or detecting a hemizygous ABCD1 pathogenic variant on molecular testing. Heterozygous female carriers of a pathogenic ABCD1 allele are usually not seriously affected and can be detected with molecular testing.
- Diagnostic confirmation of X-linked adrenoleukodystrophy
- Carrier testing in family members of the affected patient
- For the prenatal diagnosis of known familial mutation(s) in at-risk pregnancies
Negative for mutation or pathogenic variant in ABCD1 gene
Whole blood (EDTA), skin biopsy, cultured cells.
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: unacceptable
- Biochim Biophys Acta. 2006;1763: 1721-32. [PMID: 16949688]
- Arch Neurol. 2006;63: 69-73. [PMID: 16401737]
- J Pediatr. 2005;146: 528-32. [PMID: 15812458]
- JAMA. 2005;294: 3131-4. [PMID: 16380594]
- Pediatr Transplant. 2005;9 Suppl 7: 55-62. [PMID: 16305618]
- Curr Opin Neurol. 2004;17: 263-9. [PMID: 15167059]
- Genetics Home Reference. Available: https://ghr.nlm.nih.gov/condition/x-linked-adrenoleukodystrophy#
- Bertorini, T. E., & Perez, A. (2014). Neurologic complications of disorders of the adrenal glands. Handbook of Clinical Neurology, 749–771. doi:10.1016/b978-0-7020-4087-0.00050-4